It is concentrating on the development of new biopharmaceuticals using antibody technology, RNA, and proteins. The goal is to develop innovative biopharmaceuticals based on biotechnology to solve unmet demand for diseases for which there is no treatment. Amgen Korea announced on the 26th that from July last year to the beginning of this year, it was working with three companies with promising technologies to develop new drugs and focusing on various research and development cooperation based on biotechnology. According to the contents of the cooperation with the companies Amgen Korea has cooperated with, it has signed a research alliance with Generate Biomedicines to develop protein therapeutics using a machine learning-based platform, and cooperated with Arrakis Therapeutics to develop small molecules that degrade RNA. Arachis Therapeutics Selectively Destroys RNA... Started Developing'Small Molecular Therapeutics' On January 11, this year, Amgen and Arakis Therapeutics signed an agreement to develop new'RNA-degrading small molecule drugs'.

On Jan. 11, 2020, Chinese authorities shared the genetic sequence of the virus that causes COVID-19 for the first time. By Jan. 13, the biotechnology firm Moderna had used this information to finalize the design of its vaccine. This miracle of modern science -- shortening to a matter of hours a process that had previously taken months or years -- was not a stroke of luck. It was enabled by significant advancements in AI and machine learning, investments in these technologies by industry, and a research base built by decades of U.S. government funding in life sciences and biotechnology. AI is transforming the biotechnology sector, and the U.S. government should take bold steps now to realize the important influence AI will have on the sector's overall potential, and ensure the United States leads the coming biotechnology revolution.